The Take2 Prophecy™ Test for Nasopharyngeal Cancer
Nasopharyngeal cancer (NPC) is prevalent in southeast Asia and southern China, with an exceptionally high incidence in Guangdong, Guangxi, and Hong Kong. Therefore it is also known as “Guangdong cancer” or “Guangdong tumor.”
Patients with early detection of NPC have a survival rate of 90% in the next five years. On the other hand, the survival rate for patients diagnosed as in the advanced stage is less than 70% in the coming five years.
Take2 Prophecy™ Test for Nasopharyngeal Cancer (NPC) utilizes Next-generation Sequencing (NGS) technology that achieves >97% sensitivity and a 0.7% low false-positive rate. Providing accurate and reliable results, the Take2 Prophecy™ Test for NPC ranks at the top over other similar tests. It only requires a blood draw to identify early-stage NPC patients effectively.
| The Take2 Prophecy™ Test for Nasopharyngeal Cancer EBV_Take2 | |
|---|---|
| Symptoms of NPC | |
| Nosebleed, headache, tinnitus, lymph node enlargement, one-sided headache, hearing loss, facial numbness, swallowing difficulty and hoarse voice, etc | |
| Risk Factor | |
| Family History | |
| Smoking | |
| Having A diet rich in salt-cured food | |
| Frequent exposure for formaldehyde or chemicals | |
| Frequent exposure to other carcinogens | |
| Characteristics | |
| Researched and developed by the research team of the Chinese University of Hong Kong, utilizing Next-generation Sequencing technology for early-stage nasopharyngeal cancer screening | |
| with high sensitivity (>97%) and low false-positive rate (0.7%), very few cases of NPC would be missed | |
| non-invasive procedure and no hospital admission required clinically proven by thousands of individuals | |
| Not suitable for : | |
| had organ transplant | |
| currently have cancer or autoimmune diseases | |
| currently receiving systemic glucocorticoid | |
| currently receiving immunosuppressive treatment is not recommended for early NPC detection using our test | |
| HKD$1,850 |